Impact of ICCAN on Cancer Treatment Completion and Quality of Life
NCT ID: NCT01742143
Last Updated: 2025-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
347 participants
OBSERVATIONAL
2012-11-30
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
iCanWork: A Randomized Controlled Trial
NCT05546736
Implementation of a Health System Intervention to Improve Quality of Cancer Care for Rural Patients
NCT05645328
Feasibility of a Self-Management + Peer Mentoring Intervention for Adolescent and Young Adult Childhood Cancer Survivors
NCT04075734
Adolescent and Young Adult Cancer Survivors: Identity Development
NCT00832325
A Study of a Distress Screening and Referral Program in People With Recently Diagnosed Cancer
NCT07117461
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase I: Refinement
10 Black, Hispanic, and/or low-SES patients with TNBC (5 Spanish-speaking), will be recruited from MSK
The Integrated Cancer Care Access Network (ICCAN)
Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.
Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.
Phase II, Arm 1: Usual and Customary Care (U&C)
Participants in this group will receive the same referrals on social and economic resources as ICCAN group.
Usual and Customary Group (U&C)
Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.
Chart review at 3 mo, 6 mo and 1 year, and as needed.
Phase II, Arm 2: ICCAN-IO
Arm 2 will consist of everything in Arm 1
The Integrated Cancer Care Access Network (ICCAN)
Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.
Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The Integrated Cancer Care Access Network (ICCAN)
Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.
Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.
Usual and Customary Group (U&C)
Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.
Chart review at 3 mo, 6 mo and 1 year, and as needed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* fluent in English, Spanish, or Mandarin
* between the ages of 21-80 years old
* cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or
* scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients)
* planning on remaining in the area for at least 1 year
Clinician is eligible if he/she:
* Has an MD or DO degree
* Is the treating physician providing care to a patient enrolled to the study
ICCAN-IO Phase 1: Refinement, participant is eligible if he/she per EMR or self-report:
* Is 18 - 85 years of age
* Has unresectable locally advanced, locally recurrent unresectable, metastatic, or high risk/early stage TNBC or stage I-IV lung cancer
* Eligible for FDA approved immunotherapy in the NYC metropolitan area (per self-report or per MSK patient EMR records).
* Is treated in the NY metropolitan area
* Self-identifies as Black or Hispanic, and/or is low-SES (low SES will be defined as household income \< 200% of federal poverty level)
* Has English or Spanish proficiency
* Agrees to be audio-recorded
ICCAN-IO Phase 2: Pilot RCT, participant is eligible if he/she per EMR or self-report:
* Is 18 - 85 years of age
* Has stage II-III TNBC
* Treated at MSK Manhattan or OneMSK regional sites
* Self identifies as Black or Hispanic, and/or is low SES (low SES will be defined as household income \< 200% of federal poverty level)
* Has English or Spanish proficiency
* Agrees to be audio-recorded
ICCAN-IO process evaluation study team participants only:
* Staff member who serves as an Access Facilitator
* Agrees to be audio-recorded
Exclusion Criteria
* Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent
ICCAN-IO Phase 1: Refinement, participant is ineligible if he/she per EMR or self-report:
* Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
* Participants or family members who are participating in MSK IHCD studies related to social determinants of health
ICCAN-IO Phase 2: Pilot RCT, participant is ineligible if he/she per EMR or self-report:
* Presence of untreated psychiatric disturbance (e.g, acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
* Participants or family members who are participating in MSK IHCD studies related to social determinants of health
21 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
The City College of New York
OTHER
Ralph Lauren Center for Cancer Care and Prevention
OTHER
Lincoln Medical and Mental Health Center
OTHER
Lutheran Medical Center
UNKNOWN
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francesca Gany, MD, MS
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States
Lutheran Medical Center
Brooklyn, New York, United States
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
Commack, New York, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States
City College of New York (Data Collection AND Data Analysis)
New York, New York, United States
Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities)
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Rockville Centre, New York, United States
Lincoln Hospital and Mental Health Center
The Bronx, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Francesca Gany, MD, MS
Role: CONTACT
Jennifer Leng, MD, MPH
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Francesca Gany, MD, MS
Role: primary
Fransecsa Gany, MD, MS
Role: primary
Francesca Gany, MD, MS
Role: primary
Francesca Gany, MD, MS
Role: primary
Francesca Gany, MD, MS
Role: primary
Francesca Gany, MD
Role: primary
Francesca Gany, MD, MS
Role: primary
Jennifer Leng, MD, MPH
Role: backup
Franscesca Gany, MD, MS
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Gany F, Melnic I, Li Y, Finik J, Wu M, Ramirez J, Hwang C, Leng J, Blinder V. A Randomized Controlled Trial of the Integrated Cancer Care Access Network on Cancer Treatment Completion and Quality of Life. J Natl Compr Canc Netw. 2025 Jun 10;23(7):e257017. doi: 10.6004/jnccn.2025.7017.
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12-223
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.